EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced that it has demonstrated full compliance with the $1.00 minimum closing bid price requirement of Marketplace Rule 4310(c)(4) and all other requirements necessary for continued listing on the Nasdaq Capital Market. A letter from the Nasdaq Listing Qualifications Panel, to that effect, was received by the Company today.
